BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...

ALAMEDA, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ (http ...

BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the ...

Company says it estimates initial annual revenue of approximately $1 million ORLANDO, Fla. -- Sequiam Corporation, through its wholly-owned subsidiary Sequiam Biometrics, Inc.

On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D.

Geron's stem cell assets were given a new lease in early January when former CEO Tom Okarma, now heading a subsidiary of BioTime of Alameda, California, signed a definitive agreement for the latter to ...

ALAMEDA, Calif.-(BUSINESS WIRE)- BioTime, Inc. (OTCBB:BTIM) announced today that Walter Funk, Ph.D. has joined its management team as Vice President for Stem Cell Research. Dr. Funk will participate ...